PL1961420T3 - Środek do zapobiegania i leczenia ostrej niewydolności nerek - Google Patents

Środek do zapobiegania i leczenia ostrej niewydolności nerek

Info

Publication number
PL1961420T3
PL1961420T3 PL06834797T PL06834797T PL1961420T3 PL 1961420 T3 PL1961420 T3 PL 1961420T3 PL 06834797 T PL06834797 T PL 06834797T PL 06834797 T PL06834797 T PL 06834797T PL 1961420 T3 PL1961420 T3 PL 1961420T3
Authority
PL
Poland
Prior art keywords
prevention
agent
treatment
renal failure
acute renal
Prior art date
Application number
PL06834797T
Other languages
English (en)
Inventor
Soroku Yagihashi
Saori Ogasawara
Chihiro Hibi
Noriaki Kato
Original Assignee
Sanwa Kagaku Kenkyusho Co
Univ Hirosaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co, Univ Hirosaki filed Critical Sanwa Kagaku Kenkyusho Co
Publication of PL1961420T3 publication Critical patent/PL1961420T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL06834797T 2005-12-16 2006-12-15 Środek do zapobiegania i leczenia ostrej niewydolności nerek PL1961420T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005362579 2005-12-16
PCT/JP2006/325054 WO2007069727A1 (ja) 2005-12-16 2006-12-15 急性腎不全の予防または治療剤
EP06834797A EP1961420B1 (en) 2005-12-16 2006-12-15 Agent for prevention and treatment of acute renal failure

Publications (1)

Publication Number Publication Date
PL1961420T3 true PL1961420T3 (pl) 2012-12-31

Family

ID=38163029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06834797T PL1961420T3 (pl) 2005-12-16 2006-12-15 Środek do zapobiegania i leczenia ostrej niewydolności nerek

Country Status (12)

Country Link
US (1) US20080319038A1 (pl)
EP (1) EP1961420B1 (pl)
JP (1) JP5107053B2 (pl)
KR (1) KR101350226B1 (pl)
CN (1) CN101325952B (pl)
AU (1) AU2006325947B2 (pl)
CA (1) CA2633481C (pl)
DK (1) DK1961420T3 (pl)
ES (1) ES2393271T3 (pl)
HK (1) HK1126123A1 (pl)
PL (1) PL1961420T3 (pl)
WO (1) WO2007069727A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038995A2 (ko) 2008-10-02 2010-04-08 주식회사 엘지화학 광학 필름 및 이의 제조방법
DK2524693T3 (da) 2010-01-14 2014-08-25 Sanwa Kagaku Kenkyusho Co Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet
US20130005698A1 (en) 2010-04-28 2013-01-03 University Of Tsukuba Pharmaceutical for preventing or treating an inner ear disorder
JP2015110525A (ja) * 2012-04-02 2015-06-18 株式会社三和化学研究所 歯肉炎の予防又は治療のための医薬
WO2019060720A1 (en) 2017-09-25 2019-03-28 Case Western Reserve University COMPOSITIONS AND METHODS FOR REDUCING SERUM CHOLESTEROL AND PCSK9
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
WO2016090373A1 (en) * 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
US11931339B2 (en) 2018-06-25 2024-03-19 Case Western Reserve University Compositions and methods for treating tissue injury
JP2022502368A (ja) 2018-09-21 2022-01-11 ケース ウエスタン リザーブ ユニバーシティ アルドケトレダクターゼ阻害剤およびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61200991A (ja) * 1985-03-04 1986-09-05 Sanwa Kagaku Kenkyusho:Kk スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
EP0264586B1 (en) * 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
US5164391A (en) * 1989-09-20 1992-11-17 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes and circulatory diseases
JP2997892B2 (ja) * 1990-10-05 2000-01-11 株式会社三和化学研究所 ヒダントイン誘導体を有効成分とする循環器系疾患の予防及び治療剤
JP2997894B2 (ja) 1990-11-07 2000-01-11 株式会社三和化学研究所 循環器系疾患の予防及び治療剤
JP3267698B2 (ja) 1992-10-27 2002-03-18 株式会社三和化学研究所 ヒダントイン誘導体及びその塩並びにこれらを有効成分とするメイラード反応阻害剤
JPH07242547A (ja) 1994-03-02 1995-09-19 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病性単純網膜症の進行阻止剤乃至治療剤
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
US6127367A (en) * 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US6998404B2 (en) 2001-08-08 2006-02-14 Genomed, Llc Treatment or prevention of acute renal failure
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
WO2003105864A1 (en) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
JP2004300153A (ja) * 2003-03-20 2004-10-28 Kiyoshi Kurokawa 蛋白修飾物生成抑制剤
CA2543404A1 (en) * 2003-10-24 2005-05-06 Meiji Seika Kaisha, Ltd. Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor
ATE555117T1 (de) * 2004-01-30 2012-05-15 Sanwa Kagaku Kenkyusho Co Therapeutisches mittel gegen diabetisches makulaödem
US20070299119A1 (en) * 2004-02-20 2007-12-27 Sanwa Kagaku Kenkyusho Co., Ltd. Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy

Also Published As

Publication number Publication date
AU2006325947A1 (en) 2007-06-21
DK1961420T3 (da) 2012-08-27
WO2007069727A1 (ja) 2007-06-21
CA2633481A1 (en) 2007-06-21
ES2393271T3 (es) 2012-12-19
CN101325952B (zh) 2012-02-08
EP1961420A1 (en) 2008-08-27
JP5107053B2 (ja) 2012-12-26
CN101325952A (zh) 2008-12-17
KR20080097400A (ko) 2008-11-05
EP1961420B1 (en) 2012-07-25
AU2006325947B2 (en) 2011-09-01
EP1961420A4 (en) 2010-12-15
HK1126123A1 (en) 2009-08-28
JPWO2007069727A1 (ja) 2009-05-28
CA2633481C (en) 2013-12-17
US20080319038A1 (en) 2008-12-25
KR101350226B1 (ko) 2014-01-13

Similar Documents

Publication Publication Date Title
HK1126123A1 (en) Agent for prevention and treatment of acute renal failure
EP2004630A4 (en) 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
LT1921077T (lt) Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai
ZA200707472B (en) Diosmetin derivatives for the treatment and prevention of thrombotic pathologies
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
PT2520295T (pt) Métodos para prevenir e tratar a mucosite
EP1950209A4 (en) TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
EP1884238A4 (en) AGENTS WITH OBESITY ACTIVITY AND OBESITY INHIBITION PROCEDURE
EP1905452A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
IL207325A0 (en) Agent for regeneration and/or protection of nerves
IL183520A0 (en) Preventive or therapeutic agent for sleep disorder
IL197766A0 (en) Use of oritavancin for the prevention and treatment of anthrax
EP1810689A4 (en) MEANS FOR THE PREVENTION AND / OR TREATMENT OF DIABETES
ZA200709561B (en) Agent for prophylaxis and treatment of pancreatitis
EP2061484A4 (en) TREATMENT, PREVENTION AND REVERSAL OF ALCOHOL-INDUCED LIVER DISEASES
EP1953164A4 (en) THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST FUNCTIONAL ENDURANCE
IL197533A0 (en) Composition for the treatment and/or prevention of fire blight
EP1959982A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND / OR TREATING PANCREATITIS
IL194463A0 (en) Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
IL196983A0 (en) Treatment and prevention of intestinal fibrosis
EP1857119A4 (en) AGENT FOR THE PREVENTION / TREATMENT OF NEURODEGENERATIVE DISEASE
EP1776956A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT FOR CALCIPENIA
IL200377A (en) Causes the prevention, treatment and / or symptom relief of dysuria and its uses